ME1

Across TCGA pan-cancer cohorts, ME1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ME1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ME1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ME1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where ME1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.508	0.315	<.001	73	view →
CCRCC	DFS	Median	All	0.456	0.973	<.001	24	view →
UCEC	DFS	Tertile	II,III,IV	0.501	1.000	.008	18	view →
GBM	OS	Median	All	0.427	0.647	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ME1–PDAC (DFS)

Open the PDAC breakdown →